A 483 issued to Impax Labs oral solid facility in Taiwan in late July underscores FDA’s current concern with overreliance on a component supplier’s certificate of analysis (see IPQ April 17, 2014 and July 27, 2014). Other of the 10 observations on the 483 address equipment validation, specification testing, rejection of OOS product, and process validation.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
